title: [Progress of study on drug therapy in adults patients with acute myeloid leukemia (non APL) after remission].
abstract: Acute myeloid leukemia (non APL) is a group of highly heterogeneous hematologic malignancy.In recent years, after the standard "3+7" regimen, the complete remission rate of adult patients with AML (non-APL) can be as high as 70%-80%. However, due to the existence of minimal residual disease after remission, the recurrence of the disease still inevitable, only approximately 20% to 30% of the patients enjoy longterm disease-free survival. Currently only allogeneic hematopoietic stem cell transplantation is one of the most effective treatment ways for AML. The number of transplant patients is limited, because of various reasons, such as the physical condition of patients, donor sources or economic reason. After transplantation, patients also have the possibility of recurrence, therefore, drug treatment is still important after AML remission. At present, NCCN (National Comprehensive Cancer Network) recommended high-dose cytarabine as first-line postremission therapy for patients of good prognosis group and as second-line therapy for intermediate risk group. In recent years, researchers have explored other drugs, such as the nucleoside analogues, methyltransferase inhibitors and protease inhibitors or other drugs for the treatment of adult AML patients who is in remission.In this article, the treatment of conventional medicine for the treatment of AML after complete remission is summarized.
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China.
authors.forename: Feng-Mei
authors.initials: FM
authors.lastname: Lan
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China. E-mail: lihuimin@medmail.com.cn.
authors.forename: Hui-Min
authors.initials: HM
authors.lastname: Li
mesh_terms: D003561:Cytarabine; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007951:Leukemia, Myeloid; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine